{"symbol": "AKTX", "name": "Akari Therapeutics,", "next_earnings_utc": 1593518400, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1593475200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": 0.0, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "akaritx.com", "year_founded": null, "street_address": "75/76 Wimpole Street", "city": "London", "state": null, "zipcode": "W1G 9RT", "country": "United Kingdom", "phone_number": "44 20 8004 0270", "short_description": "Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases.", "long_description": "Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barr\u00c3\u00a9 syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 58607068, "total_enterprise": 52875377, "number_of_employees": 10, "outstanding_shares": 28728955, "eps": -0.869096, "diluted_eps": -0.927415, "earnings_from_cont_operations": -17945570, "gross_profit": null, "cash": 7822180, "total_debt": 0, "total_revenue": null, "cash_from_operations": -12918313, "net_income": -17105791, "ebitda": -16943915, "year_low_stock_price": 0.87, "year_high_stock_price": 3.35, "seekingalpha_follower_count": 3219, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/AKTX.png"}